Form 4: Tandem Diabetes Care Executive Receives Stock Units

Elizabeth Gasser, EVP, Chief Strategy Officer at Tandem Diabetes Care, was granted 29,136 Restricted Stock Units on May 29, 2026.

Summary

• Elizabeth Gasser, Executive Vice President and Chief Strategy Officer of Tandem Diabetes Care Inc., was granted 29,136 Restricted Stock Units (RSUs) on May 29, 2026.
• These RSUs represent a contingent right to receive either one share of the company's common stock or cash in lieu thereof.
• Vesting of the RSUs is staggered: one-third will vest on May 29, 2027, with the remaining RSUs vesting in eight equal quarterly installments thereafter.
• The grant is subject to the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended.
• A Power of Attorney was filed, authorizing Jerilyn Laskie to act on behalf of Elizabeth Gasser for SEC filings.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine executive compensation in the form of stock units, without immediate financial performance indicators or significant strategic shifts.

Positives

• Grant of Restricted Stock Units to a key executive, indicating potential alignment of executive interests with shareholder value.
• Staggered vesting schedule encourages long-term commitment from the executive.
• The grant is part of an established incentive plan, suggesting a structured approach to executive compensation.

Risks

• The value of the RSUs is contingent on the future performance and stock price of Tandem Diabetes Care.
• Vesting is subject to the terms of the 2023 Plan, which may include performance conditions not detailed in this filing.

Future Outlook

The future outlook for the RSUs is tied to the vesting schedule, with portions vesting on May 29, 2027, and subsequent quarterly installments thereafter, contingent upon the terms of the 2023 Long-Term Incentive Plan.

Industry Context

StockSavvy.ai notes that the issuance of Restricted Stock Units to executives is a common practice in the medical device industry, including diabetes care, to incentivize performance and retain talent.

Stakeholder Impact

• Shareholders: The grant of RSUs can be viewed positively as it aligns executive incentives with long-term company performance and stock value.
• Employees: May indicate a stable compensation structure for executives, potentially reflecting positively on overall company stability.
• Management: Reinforces the executive's role and commitment through equity-based compensation.

Next Steps

• Vesting of one-third of RSUs on May 29, 2027.
• Subsequent quarterly vesting of remaining RSUs.
• Continued adherence to the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, Form 4, Restricted Stock Units, RSU, Executive Compensation, Stock Options, Insider Trading, SEC Filing, Elizabeth Gasser